[Cutaneous pigmentation disorders in human immunodeficiency virus infection].
D000163:Acquired Immunodeficiency Syndrome / Q000150:complications*; D000309:Adrenal Insufficiency / Q000150:complications; D000998:Antiviral Agents / Q000009:adverse effects; D001761:Bleomycin / Q000009:adverse effects; D002991:Clofazimine / Q000009:adverse effects; D005260:Female; D015658:HIV Infections / Q000150:complications*; D006432:Hemochromatosis / Q000150:complications; D006801:Humans; D017495:Hyperpigmentation / Q000209:etiology; D017496:Hypopigmentation / Q000209:etiology; D007654:Ketoconazole / Q000009:adverse effects; D008297:Male; D010859:Pigmentation Disorders / Q000139:chemically induced / Q000209:etiology*; D012880:Skin Pigmentation
D000998:Antiviral Agents; D001761:Bleomycin; D002991:Clofazimine; D007654:Ketoconazole
Troubles de la pigmentation cutanée au cours de l'infection par le virus de l'immunodéficience humaine.